K V Kowdley

Summary

Affiliation: University of Washington
Country: USA

Publications

  1. ncbi Motion - prophylactic banding of esophageal varices is useful: arguments against the motion
    Kris V Kowdley
    Division of Gastroenterology and Hepatology, University of Washington School of Medicine, Seattle 98195, USA
    Can J Gastroenterol 16:693-5. 2002
  2. ncbi Iron, hemochromatosis, and hepatocellular carcinoma
    Kris V Kowdley
    University of Washington, Box 356174, 1959 NE Pacific Street, Seattle, Washington 98195, USA
    Gastroenterology 127:S79-86. 2004
  3. ncbi Survival after liver transplantation in patients with hepatic iron overload: the national hemochromatosis transplant registry
    Kris V Kowdley
    University of Washington, Seattle, 98195, USA
    Gastroenterology 129:494-503. 2005
  4. ncbi Iron Overload (with Attention to Genetic Testing and Diagnosis/Management of HFE Wild Type Patients)
    Narendra Siddaiah
    University of Washington Medical Center, 1959 NE Pacific Street, Box 356174, Seattle, WA98195, USA
    Curr Treat Options Gastroenterol 9:447-55. 2006
  5. ncbi Lipids and lipid-activated vitamins in chronic cholestatic diseases
    K V Kowdley
    Division of Gastroenterology and Hepatology, University of Washington School of Medicine, Seattle, Washington 98195, USA
    Clin Liver Dis 2:373-89, x. 1998
  6. ncbi Hematologic side effects of interferon and ribavirin therapy
    Kris V Kowdley
    University of Washington, Seattle, WA 98195, USA
    J Clin Gastroenterol 39:S3-8. 2005
  7. ncbi Utility of hepatic iron index in American patients with hereditary hemochromatosis: a multicenter study
    K V Kowdley
    Department of Medicine, University of Washington School of Medicine, Seattle, USA
    Gastroenterology 113:1270-7. 1997
  8. ncbi Cognitive impairment and intracranial calcification in chronic hypoparathyroidism
    K V Kowdley
    Bone and Mineral Research Unit, Portland VA Medical Center, Oregon Health Sciences University, USA
    Am J Med Sci 317:273-7. 1999
  9. ncbi Management strategies for ribavirin-induced hemolytic anemia in the treatment of hepatitis C: clinical and economic implications
    E B Devine
    University of Washington, Department of Pharmacy, Box 357630, Seattle, WA 98195 7630, USA
    Value Health 4:376-84. 2001
  10. ncbi Primary placement of Palmaz long medium stents in transjugular intrahepatic portosystemic shunts
    J J Borsa
    Department of Radiology, University of Washington Medical Center, Seattle 98195, USA
    J Vasc Interv Radiol 11:189-94. 2000

Detail Information

Publications92

  1. ncbi Motion - prophylactic banding of esophageal varices is useful: arguments against the motion
    Kris V Kowdley
    Division of Gastroenterology and Hepatology, University of Washington School of Medicine, Seattle 98195, USA
    Can J Gastroenterol 16:693-5. 2002
    ..It is hoped that additional large, multicentre trials of band ligation versus beta-blockers will examine the efficacy, cost effectiveness and impact on quality of life among patients with cirrhosis...
  2. ncbi Iron, hemochromatosis, and hepatocellular carcinoma
    Kris V Kowdley
    University of Washington, Box 356174, 1959 NE Pacific Street, Seattle, Washington 98195, USA
    Gastroenterology 127:S79-86. 2004
    ....
  3. ncbi Survival after liver transplantation in patients with hepatic iron overload: the national hemochromatosis transplant registry
    Kris V Kowdley
    University of Washington, Seattle, 98195, USA
    Gastroenterology 129:494-503. 2005
    ..We examined the effect of HFE mutations on posttransplantation survival in patients with hepatic iron overload...
  4. ncbi Iron Overload (with Attention to Genetic Testing and Diagnosis/Management of HFE Wild Type Patients)
    Narendra Siddaiah
    University of Washington Medical Center, 1959 NE Pacific Street, Box 356174, Seattle, WA98195, USA
    Curr Treat Options Gastroenterol 9:447-55. 2006
    ..Phlebotomy remains the mainstay of therapy also for non-HFE hemochromatosis. However, phlebotomy may not be well tolerated in certain forms of non-HFE hemochromatosis such as "ferroportin disease."..
  5. ncbi Lipids and lipid-activated vitamins in chronic cholestatic diseases
    K V Kowdley
    Division of Gastroenterology and Hepatology, University of Washington School of Medicine, Seattle, Washington 98195, USA
    Clin Liver Dis 2:373-89, x. 1998
    ..This article focuses on abnormalities in lipid metabolism in primary biliary cirrhosis and primary sclerosing cholangitis, and on lipid-activated vitamin deficiencies in these disorders...
  6. ncbi Hematologic side effects of interferon and ribavirin therapy
    Kris V Kowdley
    University of Washington, Seattle, WA 98195, USA
    J Clin Gastroenterol 39:S3-8. 2005
    ..The incidence, magnitude, and possible mechanisms of hematologic complications associated with interferon and ribavirin are described in this review...
  7. ncbi Utility of hepatic iron index in American patients with hereditary hemochromatosis: a multicenter study
    K V Kowdley
    Department of Medicine, University of Washington School of Medicine, Seattle, USA
    Gastroenterology 113:1270-7. 1997
    ..There are limited data on the diagnostic use of the hepatic iron index in patients with HHC in the United States. This study evaluated the hepatic iron index in the diagnosis of HHC in a multicenter U.S. study...
  8. ncbi Cognitive impairment and intracranial calcification in chronic hypoparathyroidism
    K V Kowdley
    Bone and Mineral Research Unit, Portland VA Medical Center, Oregon Health Sciences University, USA
    Am J Med Sci 317:273-7. 1999
    ..The purpose of this study was to determine whether chronic hypoparathyroidism is associated with cognitive impairment...
  9. ncbi Management strategies for ribavirin-induced hemolytic anemia in the treatment of hepatitis C: clinical and economic implications
    E B Devine
    University of Washington, Department of Pharmacy, Box 357630, Seattle, WA 98195 7630, USA
    Value Health 4:376-84. 2001
    ..The objective of this study was to evaluate the direct health-care costs and management of RIHA during treatment of CHC in a clinical trial setting...
  10. ncbi Primary placement of Palmaz long medium stents in transjugular intrahepatic portosystemic shunts
    J J Borsa
    Department of Radiology, University of Washington Medical Center, Seattle 98195, USA
    J Vasc Interv Radiol 11:189-94. 2000
    ..To describe our results with primary placement of the long-medium Palmaz stent for transjugular intrahepatic portosystemic shunts (TIPS)...
  11. ncbi The role of iron in the pathophysiology and treatment of chronic hepatitis C
    Leslie Price
    Center for Liver Disease, Virginia Mason Medical Center, Seattle, Washington 98101, USA
    Can J Gastroenterol 23:822-8. 2009
    ..The present article reviews the prevalence and risk factors for hepatic iron overload in chronic hepatitis C, with emphasis on the available data regarding the efficacy of iron depletion in the treatment of this common liver disease...
  12. ncbi Hepatitis C, iron status, and disease severity: relationship with HFE mutations
    Bruce Y Tung
    Department of Medicine, University of Washington School of Medicine, Seattle, USA
    Gastroenterology 124:318-26. 2003
    ..We sought to determine whether mutations in the hemochromatosis gene, HFE, are associated with iron overload and acceleration of disease progression in hepatitis C patients...
  13. ncbi Relationships between hepatic iron content and virologic response in chronic hepatitis C patients treated with interferon and ribavirin
    Stephen J Rulyak
    Department of Medicine, Division of Gastroenterology, University of Washington, 1959 NE Pacific Street, Seattle, WA 98195, USA
    Am J Gastroenterol 100:332-7. 2005
    ..73). CONCLUSIONS: Pretreatment HIC is not an independent predictor of response to therapy with interferon and ribavirin. Combination therapy does not significantly change HIC regardless of baseline histology or virologic response...
  14. ncbi The cost of treating ribavirin-induced anemia in hepatitis C: the impact of using recombinant human erythropoietin
    E B Devine
    University of Washington Department of Pharmacy, Seattle, WA 98195 7630, USA
    Curr Med Res Opin 23:1463-72. 2007
    ..The secondary objective was to calculate the incremental cost of using epoetin versus no epoetin to treat RIA, per ribavirin dose reduction/discontinuation averted...
  15. ncbi Differences in hepatic phenotype between hemochromatosis patients with HFE C282Y homozygosity and other HFE genotypes
    Raymond Cheng
    Department of Medicine, University of Washington, Seattle, WA, USA
    J Clin Gastroenterol 43:569-73. 2009
    ..The goal of this study was to compare hepatic histopathologic features and hepatic iron concentration (HIC) among patients with phenotypic hemochromatosis and different HFE genotypes...
  16. ncbi Optimal duration of therapy in HBV-related cirrhosis
    Carmen Y Lim
    University of Washington Medical Center, Box 356174, 1959 NE Pacific Street, Seattle, WA 98195, USA
    J Antimicrob Chemother 60:2-6. 2007
    ..This article describes the current recommendations regarding therapy in this group of patients and suggests some criteria for treatment of patients with chronic hepatitis B-related cirrhosis or advanced hepatic fibrosis...
  17. ncbi Non-HFE hemochromatosis: genetics, pathogenesis, and clinical management
    James E Nelson
    Department of Medicine, Division of Gastroenterology, University of Washington Medical Center, 1959 NE Pacific Street, Box 356424, Seattle, WA 98195, USA
    Curr Gastroenterol Rep 7:71-80. 2005
    ..Management generally consists of periodic phlebotomies until iron is depleted...
  18. ncbi Prevalence of hepatic iron overload and association with hepatocellular cancer in end-stage liver disease: results from the National Hemochromatosis Transplant Registry
    Cynthia Ko
    Division of Gastroenterology, University of Washington Medical Center, Seattle, WA, USA
    Liver Int 27:1394-401. 2007
    ..This study examined the association between hepatic iron grade and hepatocellular carcinoma in patients with end-stage liver disease of diverse aetiologies...
  19. ncbi Effect of alcohol on viral hepatitis and other forms of liver dysfunction
    Sripriya Balasubramanian
    Division of Gastroenterology and Hepatology, University of California at Davis, 4150 V Street #3500, Sacramento, California 95817, USA
    Clin Liver Dis 9:83-101. 2005
    ..Examples of liver diseases that are significantly influenced by ingestion of alcohol include chronic viral hepatitis, disorders of iron overload, and obesity-related liver disease...
  20. ncbi Serum ferritin level predicts advanced hepatic fibrosis among U.S. patients with phenotypic hemochromatosis
    Elizabeth D Morrison
    University of Washington, Seattle, Washington 98195, USA
    Ann Intern Med 138:627-33. 2003
    ..Liver biopsy to screen for cirrhosis may be unnecessary in such patients, regardless of age or serum liver enzyme levels...
  21. ncbi An evaluation of the potential cost-effectiveness of non-invasive testing strategies in the diagnosis of significant liver fibrosis
    Josh J Carlson
    Institute for Public Health Genetics, School of Public Health and Community Medicine, University of Washington, Washington 98195, USA
    J Gastroenterol Hepatol 24:786-91. 2009
    ..To assess the clinical and economic outcomes of non-invasive testing strategies in the diagnosis of significant liver fibrosis (Metavir score >or= 2) compared with liver biopsy...
  22. ncbi Effect of iron depletion on serum markers of fibrogenesis, oxidative stress and serum liver enzymes in chronic hepatitis C: results of a pilot study
    Jacob Alexander
    Department of Medicine, Division of Gastroenterology, University of Washington Medical Center, Seattle, WA, USA
    Liver Int 27:268-73. 2007
    ..We performed this study to evaluate the effect of iron depletion on biochemical and virologic markers, and markers of lipid peroxidation and fibrogenesis...
  23. ncbi The importance of screening for hemochromatosis
    Suja DuBois
    Division of Gastreonterology/ Hepatology, University of Washington School of Medicine, Seattle, WA 98195, USA
    Arch Intern Med 163:2424-6; author reply 2426. 2003
  24. ncbi Hereditary hemochromatosis: a review of the genetics, mechanism, diagnosis, and treatment of iron overload
    Cathrine J Wheeler
    Department of Medicine, University of Washington, Seattle, WA 98195, USA
    Compr Ther 32:10-6. 2006
    ..Early diagnosis and initiation of therapeutic phlebotomy can provide a normal life expectancy for affected individuals...
  25. ncbi HFE C282Y mutations are associated with advanced hepatic fibrosis in Caucasians with nonalcoholic steatohepatitis
    James E Nelson
    University of Washington Medical Center, Seattle, WA 98195, USA
    Hepatology 46:723-9. 2007
    ..CONCLUSION: The HFE C282Y heterozygous mutation is associated with advanced fibrosis among Caucasians with NASH. Additional studies are warranted to examine the possible mechanisms for this relationship...
  26. ncbi Hepatic iron overload in alcoholic end-stage liver disease is associated with iron deposition in other organs in the absence of HFE-1 hemochromatosis
    Sue C Eng
    Department of Medicine, University of Washington Medical Center Seattle, WA 98195, USA
    Liver Int 25:513-7. 2005
    ..8 to 2.2 (micromol/g/years). CONCLUSION: Iron overload secondary to end-stage liver disease can be associated with iron deposition in other organs in the absence of HFE-1 HHC...
  27. ncbi Retrospective comparison of the patency of Wallstents and Palmaz long-medium stents used for TIPS. Transjugular intrahepatic portosystemic shunts
    J J Borsa
    Department of Radiology, University of Washington Medical Center, Box 357115, 1959 NE Pacific Street, Seattle, WA 98195, USA
    Cardiovasc Intervent Radiol 23:332-9. 2000
    ..To compare patency rates of transjugular intrahepatic portosystemic shunts (TIPS) after placement of long-medium Palmaz stents or Wallstents...
  28. ncbi Hereditary hemochromatosis and diabetes mellitus: implications for clinical practice
    Kristina M Utzschneider
    Division of Metabolism, Endocrinology and Nutrition, Department of Medicine, VA Puget Sound Health Care System, Seattle, WA 98108, USA
    Nat Rev Endocrinol 6:26-33. 2010
    ..Further research into the long-term effects of treatment on prevention of diabetes mellitus in HH is needed...
  29. ncbi Cost effectiveness of entecavir versus lamivudine with adefovir salvage in HBeAg-positive chronic hepatitis B
    David L Veenstra
    Pharmaceutical Outcomes Research and Policy Program, Department of Pharmacy, University of Washington, Seattle, Washington 98195, USA
    Pharmacoeconomics 25:963-77. 2007
    ..Previous economic analyses have been limited by the lack of comparative clinical data for entecavir and lamivudine beyond 1-year duration and for salvage therapy...
  30. ncbi The effect of alcohol consumption on the prevalence of iron overload, iron deficiency, and iron deficiency anemia
    George N Ioannou
    Department of Medicine and Division of Gastroenterology, University of Washington Medical Center, and VA Medical Center, 1660 S Columbian Way, Seattle, WA 98108, USA
    Gastroenterology 126:1293-301. 2004
    ..Our aim was to investigate the relationship between alcohol consumption and iron overload, iron deficiency, or iron deficiency anemia in the U.S. population...
  31. ncbi Is central obesity associated with cirrhosis-related death or hospitalization? A population-based, cohort study
    George N Ioannou
    Health Services Research and Development and Northwest Hepatitis C Resource Centers, Veterans Affairs Puget Sound System, Seattle, Washington, USA
    Clin Gastroenterol Hepatol 3:67-74. 2005
    ..We aimed to determine the interaction between body fat distribution (central versus peripheral) and increased body mass index (BMI) with regards to the risk of cirrhosis-related death or hospitalization...
  32. ncbi Relationship between transferrin-iron saturation, alcohol consumption, and the incidence of cirrhosis and liver cancer
    George N Ioannou
    Division of Gastroenterology, Department of Medicine, Veterans Affairs Puget Sound Health Care System, University of Washington, Seattle, Washington, USA
    Clin Gastroenterol Hepatol 5:624-9. 2007
    ..We examined the relation between baseline serum transferrin-iron saturation (TS) and the incidence of hospitalizations or deaths related to cirrhosis and liver cancer as well as the influence of alcohol consumption on this relationship...
  33. ncbi Natural history of nonalcoholic steatohepatitis
    Iris Liou
    Division of Gastroenterology/Hepatology, University of Washington, Seattle, WA, USA
    J Clin Gastroenterol 40:S11-6. 2006
    ..Recurrence of NASH has been described among patients who have undergone liver transplantation for NASH-related end-stage liver disease...
  34. ncbi Pilot study of the relationship between histologic progression and hepatic iron concentration in chronic hepatitis C
    Anne M Larson
    Division of Gastroenterology, University of Washington, Seattle, WA 98195, USA
    J Clin Gastroenterol 37:406-11. 2003
    ..The interaction between progression of hepatitis C and iron deposition warrants further study...
  35. ncbi Factors predictive of significant hepatic fibrosis in adults with chronic hepatitis B and normal serum ALT
    Chia C Wang
    Department of Medicine, University of Washington, Seattle, WA 98104 2499, USA
    J Clin Gastroenterol 42:820-6. 2008
    ..This study examines the prevalence and correlates of significant liver fibrosis among patients with immunotolerant hepatitis B...
  36. ncbi Is obesity a risk factor for cirrhosis-related death or hospitalization? A population-based cohort study
    George N Ioannou
    Veterans Affairs Medical Center, Health Services Research and Development, MS 152, Building 1, Room 422, 1660 South Columbian Way, Seattle, Washington 98108, USA
    Gastroenterology 125:1053-9. 2003
    ..Our aim was to determine whether increased body mass index (BMI) in the general population is associated with cirrhosis-related death or hospitalization...
  37. ncbi Induction immunosuppressive therapy is associated with a low rejection rate after liver transplantation
    J P McVicar
    Department of Surgery, University of Washington School of Medicine, Seattle, USA
    Clin Transplant 11:328-33. 1997
    ..These results suggest that use of induction therapy with cytolytic antibodies does not lead to a high incidence of CMV infection and decreases the incidence of rejection after liver transplantation...
  38. ncbi Review article: targeted screening for hereditary haemochromatosis in high-risk groups
    S Dubois
    Senior Fellow, Division of Gastroenterology, University of Washington, WA 98195, USA
    Aliment Pharmacol Ther 20:1-14. 2004
    ..We also suggest possible screening strategies based on the available evidence...
  39. ncbi Phenotypic characteristics and diagnoses of patients referred to an iron overload clinic
    John B Dever
    Digestive Disease Institute, Liver Center of Excellence, Virginia Mason Medical Center, Seattle, WA, USA
    Dig Dis Sci 55:803-7. 2010
    ..There are limited data on the phenotypic differences between patients with hereditary hemochromatosis (HH) and other forms of iron overload...
  40. ncbi Relationship between gene expression of duodenal iron transporters and iron stores in hemochromatosis subjects
    James E Nelson
    Benaroya Research Institute and Center for Liver Disease, Digestive Disease Institute, Virginia Mason Medical Center, Seattle, WA 98101, USA
    Am J Physiol Gastrointest Liver Physiol 298:G57-62. 2010
    ..There is coordinated regulation between duodenal expression of FPN1 and DMT1, FPN1 and DCYTB, and FPN1 and HEPH and also DCYTB and HEPH in HH subjects regardless of phenotype...
  41. ncbi Association of hepatic iron overload with invasive fungal infection in liver transplant recipients
    Jacob Alexander
    Division of Gastroenterology, University of Washington Medical Center, Seattle, WA 98195, USA
    Liver Transpl 12:1799-804. 2006
    ..45-6.56; P = 0.003). Hepatic iron overload is strongly and independently associated with posttransplantation invasive fungal infections. Studies to confirm this finding in other centers and define the mechanism are warranted...
  42. ncbi Evaluating anti-viral drug selection and treatment duration in HBeAg-negative chronic hepatitis B: a cost-effectiveness analysis
    D L Veenstra
    Pharmaceutical Outcomes Research and Policy Program, Department of Pharmacy, University of Washington, Seattle, WA 98195, USA
    Aliment Pharmacol Ther 27:1240-52. 2008
    ..Several anti-viral treatments are now available for HBeAg-negative chronic hepatitis B (CHB), but the clinical and economic outcomes of potential treatment strategies and durations are unclear...
  43. ncbi Risk factors for recurrence of primary sclerosing cholangitis after liver transplantation
    Jacob Alexander
    Division of Gastroenterology, Department of Medicine, University of Washington, Seattle, WA, USA
    Liver Transpl 14:245-51. 2008
    ..Further studies are required to confirm these observations and to understand the underlying mechanisms...
  44. ncbi The predictors of the presence of varices in patients with primary sclerosing cholangitis
    Sombat Treeprasertsuk
    Division of Gastroenterology and Hepatology, Mayo Clinic Rochester, Rochester, MN, USA
    Hepatology 51:1302-10. 2010
    ..Lower platelet count and higher total bilirubin at 2 years were significantly associated with an increased risk of developing new varices in patients with PSC...
  45. ncbi HFE-associated hereditary hemochromatosis
    Jacob Alexander
    Department of Medicine, University of Washington, Seattle, USA
    Genet Med 11:307-13. 2009
    ..C282Y homozygotes do not develop clinically significant iron overload. HFE gene testing remains an excellent tool for the screening of first-degree relatives of affected probands who are p.C282Y homozygotes...
  46. ncbi Racial differences in the relationship between hepatitis C infection and iron stores
    George N Ioannou
    Department of Medicine and Division of Gastroenterology, University of Washington, Seattle, WA 98195, USA
    Hepatology 37:795-801. 2003
    ..This finding may partly explain the reduced response of HCV-positive African-Americans to antiviral treatment...
  47. ncbi Prevalence and predictors of asymptomatic liver disease in patients undergoing gastric bypass surgery
    Charles Beymer
    Department of Internal Medicine, University of Washington School of Medicine, Seattle 98195-6410, USA
    Arch Surg 138:1240-4. 2003
    ..CONCLUSIONS: Moderate to severe hepatic steatosis and NASH are common among individuals undergoing gastric bypass procedures. Diabetes mellitus but not BMI is associated with NASH and advanced hepatic fibrosis in these patients...
  48. ncbi Current and future therapy in haemochromatosis and Wilson's disease
    Karen F Murray
    Hepatobiliary Program, Childrens Hospital and Regional Medical Center, and University of Washington, Seattle, WA 98195, USA
    Expert Opin Pharmacother 4:2239-51. 2003
    ..This review, will discuss the pathogenesis, and current and future therapies for iron and copper overload disorders...
  49. ncbi Hepatitis B and liver transplantation
    Bruce Y Tung
    Division of Gastroenterology, University of Washington School of Medicine, Seattle, WA 98195, USA
    Clin Infect Dis 41:1461-6. 2005
    ..Ongoing studies are necessary to establish the most cost-effective approaches to prevent recurrent hepatitis B virus infection after liver transplantation...
  50. ncbi Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial
    Keith D Lindor
    Division of Gastroenterology and Hepatology, Mayo Clinic W19A, 200 1st Street SW, Rochester, MN 55905, USA
    Hepatology 39:770-8. 2004
    ..In conclusion, 2 years of therapy with UDCA at a dose of 13 to 15 mg/kg/d, although safe and well tolerated, is not better than placebo for patients with NASH...
  51. ncbi Hereditary hemochromatosis: genetics, pathogenesis, and clinical management
    Jacob Alexander
    University of Washington, Seattle 98195, USA
    Ann Hepatol 4:240-7. 2005
    ..In this review, we describe the current state of understanding in the clinical features, pathophysiology and treatment of hereditary hemochromatosis...
  52. ncbi Silymarin in the treatment of patients with primary sclerosing cholangitis: an open-label pilot study
    Paul Angulo
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Dig Dis Sci 53:1716-20. 2008
    ..The results of this pilot study warrant further evaluation of silymarin in patients with PSC in a large-scale, controlled trial...
  53. ncbi High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis
    Keith D Lindor
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA
    Hepatology 50:808-14. 2009
    ..01]). Conclusion: Long-term, high-dose UDCA therapy is associated with improvement in serum liver tests in PSC but does not improve survival and was associated with higher rates of serious adverse events...
  54. ncbi Complications after ERCP in patients with primary sclerosing cholangitis
    Jason P Etzel
    Department of Medicine, University of Washington Medical Center, Seattle, Washington, USA
    Gastrointest Endosc 67:643-8. 2008
    ..There are conflicting data regarding the role of ERCP in patients with primary sclerosing cholangitis (PSC) and the risk of procedure-related complications...
  55. ncbi Silybin treatment is associated with reduction in serum ferritin in patients with chronic hepatitis C
    Julie M Bares
    Department of Medicine, University of Washington Medical Center, Seattle, WA, USA
    J Clin Gastroenterol 42:937-44. 2008
    ..The goal of this study was to examine the effect of a standardized silybin and soy phosphatidylcholine complex (IdB 1016) on serum markers of iron status...
  56. ncbi [Endoscopic management of biliary complications after liver transplantation]
    Christopher J Carlson
    University of Washington, Seattle 98195, USA
    Rev Gastroenterol Mex 70:107-20. 2005
    ..The results of endoscopic management of these strictures is also described in detail and should be of interest to therapeutic endoscopists, liver transplant physicians, transplant surgeons and therapeutic endoscopists...
  57. ncbi Liver transplantation for metabolic liver diseases
    Kristine Y Zhang
    Division of Gastroenterology and Hepatology, University of Washington School of Medicine, 1959 NE Pacific Street, Box 356424, Seattle, WA 98195, USA
    Clin Liver Dis 11:265-81. 2007
    ..This article reviews common metabolic liver diseases treated with liver transplantation in the adult population...
  58. ncbi Incidence of minor complications and time lost from normal activities after screening or surveillance colonoscopy
    Cynthia W Ko
    Department of Medicine, University of Washington, Seattle, WA 98195, USA
    Gastrointest Endosc 65:648-56. 2007
    ..Few studies address the development of minor complications after screening or surveillance colonoscopy...
  59. ncbi CYP2E1 activity before and after weight loss in morbidly obese subjects with nonalcoholic fatty liver disease
    Maurice G Emery
    Department of Pharmaceutics, University of Washington, Seattle, WA 98195, USA
    Hepatology 38:428-35. 2003
    ....
  60. ncbi Treating NAFLD: future prospects
    Stephen H Caldwell
    Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Virginia Health System, Charlottesville, VA 22908-0708, USA
    J Clin Gastroenterol 40:S67-8. 2006
  61. ncbi Liver involvement in patients with solid tumors of nonhepatic origin
    Renuka Bhattacharya
    Division of Gastroenterology, Department of Medicine, University of Washington, 1959 NE Pacific Street, Box 356174, Seattle, WA 98195, USA
    Clin Liver Dis 6:1033-43, x. 2002
    ..Multiple treatment modalities are available, including hepatic resection, hepatic arterial chemotherapy, systemic chemotherapy, chemoembolization, cryotherapy, ethanol injection, and radiofrequency ablation...
  62. ncbi Iron in hepatitis C: villain or innocent bystander?
    George N Ioannou
    Health Services Research and Development, Veterans Affairs Puget Sound Health Care System, University of Washington, Seattle, USA
    Semin Gastrointest Dis 13:95-108. 2002
    ..Future studies should focus on the efficacy of combining iron depletion with pegylated interferon and ribavirin and on the effect of long-term iron depletion on histologic progression of chronic hepatitis C infection...
  63. ncbi Transplantation of allogeneic T cells alters iron homeostasis in NOD/SCID mice
    Steven Bair
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Blood 113:1841-4. 2009
    ..These findings suggest that alloreactive T cell-dependent signals induced dysregulation of intestinal iron absorption, which contributed to liver iron overload after HCT...
  64. ncbi Abnormal liver test results on routine screening. How to evaluate, when to refer for a biopsy
    Mark A Mallory
    Division of Gastroenterology and Hepatology, University of Washington School of Medicine, Seattle, WA, USA
    Postgrad Med 115:53-6, 59-62, 66. 2004
    ..They also explore the considerations that might prompt physicians to request a liver biopsy...
  65. ncbi Airway obstruction complicating esophageal stent placement in two post-pneumonectomy patients
    Alexander S Farivar
    Department of Thoracic Surgery, Washington Medical Center, Seattle, Washington 98195, USA
    Ann Thorac Surg 78:e22-3. 2004
    ..Here we describe two cases in postpneumonectomy patients in which expandable esophageal stent placement resulted in respiratory compromise requiring reintervention due to airway compression...
  66. ncbi Global epidemiology of hepatitis B virus
    Brian Custer
    Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, WA, USA
    J Clin Gastroenterol 38:S158-68. 2004
    ..Preventing the most severe HBV disease consequences in infected individuals, such as cirrhosis and hepatocellular carcinoma, will require appropriate therapeutic agents...
  67. ncbi Fulminant hepatic failure secondary to neoplastic infiltration of the liver
    Pankaj Rajvanshi
    Division of Gastroenterology and Hepatology, University of Washington School of Medicine, Seattle, WA 98195-6424, USA
    J Clin Gastroenterol 39:339-43. 2005
    ..Neoplastic involvement of liver should be considered in the differential diagnosis of FHF of unknown etiology. The imaging studies in this setting can be misleading...
  68. ncbi The effect of periodic monitoring and feedback on screening colonoscopy withdrawal times, polyp detection rates, and patient satisfaction scores
    Otto S Lin
    Gastroenterology Section, Virginia Mason Medical Center, Seattle, Washington, USA
    Gastrointest Endosc 71:1253-9. 2010
    ..Previous studies showed a correlation between mean withdrawal times during screening colonoscopy and polyp/neoplasia detection rates...
  69. ncbi Management of biliary complications following orthotopic liver transplantation
    Andrew E Scanga
    Division of Gastroenterology, Department of Medicine, University of Washington Medical Center, Box 356174, 1959 NE Pacific Street, Seattle, WA 98195 6174, USA
    Curr Gastroenterol Rep 9:31-8. 2007
    ..This article focuses on the incidence, timing, mechanism, and endoscopic management of biliary leak, strictures, stones, sludge, casts, and sphincter of Oddi dysfunction following liver transplantation...
  70. ncbi Bile acid changes after high-dose ursodeoxycholic acid treatment in primary sclerosing cholangitis: Relation to disease progression
    Emmanouil Sinakos
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA
    Hepatology 52:197-203. 2010
    ..21 micromol/L, P < 0.08) in comparison with those who did not. CONCLUSION: High-dose UDCA treatment in PSC patients results in marked UDCA enrichment and significant expansion of the total serum bile acid pool, including LCA...
  71. ncbi Durability of serologic response after lamivudine treatment of chronic hepatitis B
    Jules L Dienstag
    Gastrointestinal Unit Medical Services, Massachusetts General Hospital and Department of Medicine, Harvard Medical School, Boston, MA 02114, USA
    Hepatology 37:748-55. 2003
    ..Lamivudine retreatment for reappearance of hepatitis B markers can achieve resumption of viral suppression...
  72. ncbi Hereditary hemochromatosis: time for targeted screening
    Pradyumna D Phatak
    Rochester General Hospital, 1425 Portland Avenue, Rochester, NY 14621, USA
    Ann Intern Med 149:270-2. 2008
    ..In this article, the authors draw attention again to hereditary hemochromatosis as a cause of preventable organ dysfunction and propose targeted case finding for Caucasian men of Northern European ancestry...
  73. ncbi In search of vulcan: Where are all the iron men (and women)?
    George N Ioannou
    Gastroenterology 123:948-50; discussion 950. 2002
  74. ncbi The North American Study for the Treatment of Refractory Ascites
    Arun J Sanyal
    Department of Internal Medicine, Virginia Commonwealth University Health System, Richmond, Virginia, USA
    Gastroenterology 124:634-41. 2003
    ..The clinical utility of transjugular intrahepatic portosystemic shunts (TIPS) vis-à-vis total paracentesis in the management of refractory ascites is unclear...
  75. ncbi Prediction of varices in patients with cirrhosis: a high-stakes numbers game?
    Pankaj Rajvanshi
    J Clin Gastroenterol 34:4-5. 2002
  76. ncbi Expansion of criteria for liver transplantation in HCC: a slippery slope?
    Sue C Eng
    Gastroenterology 122:579-82. 2002
  77. ncbi Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B
    Robert J Fontana
    Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI, USA
    Liver Transpl 8:433-9. 2002
    ....
  78. ncbi Iron and HFE mutations in nonalcoholic steatohepatitis: innocent bystanders or accessories to the crime?
    Renuka Bhattacharya
    Gastroenterology 125:615-6; discussion 617. 2003
  79. ncbi Hematologic side effects of PEG interferon and ribavirin. Management with growth factors
    Emmet B Keeffe
    Stanford University Medical Center, Palo Alto, CA
    J Clin Gastroenterol 39:S1-2. 2005
  80. ncbi Chemoprevention of hepatocellular carcinoma in chronic hepatitis B with lamivudine?
    Lei Y Lim
    Gastroenterology 129:2120-2; discussion 2122. 2005
  81. ncbi Where do we go from HEIRS?
    Narendra Siddaiah
    Gastroenterology 130:608-11; discussion 611. 2006
  82. ncbi Liver transplantation: an "in vivo" model for the pathophysiology of hemochromatosis?
    Kris V Kowdley
    Hepatology 39:1495-8. 2004
  83. ncbi Nonalcoholic steatohepatitis: a twenty-first century epidemic?
    Kris V Kowdley
    J Clin Gastroenterol 40:S2-4. 2006
  84. ncbi Iron, HFE mutations, and hepatocellular carcinoma: is hepatic iron a carcinogen?
    George N Ioannou
    Clin Gastroenterol Hepatol 1:246-8. 2003
  85. ncbi Neoplastic transformation of rat liver epithelial cells is enhanced by non-transferrin-bound iron
    Donald J Messner
    Bastyr University, 14500 Juanita Drive, Kenmore, WA 98028, USA
    BMC Gastroenterol 8:2. 2008
    ..The primary aim of this study was to investigate NTBI-related hepatic carcinogenesis using T51B rat liver epithelial cells, a non-neoplastic cell line previously developed for carcinogenicity and tumor promotion studies...
  86. ncbi Effects of iron and HFE mutations on response to therapy in chronic hepatitis C: an ironic interaction?
    Jacob Alexander
    Gastroenterology 131:1635-8. 2006
  87. ncbi Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis
    Burton Combes
    The University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390 9151, USA
    Hepatology 42:1184-93. 2005
    ..In conclusion, methotrexate when added to UDCA for a median period of 7.6 years had no effect on the course of PBC treated with UDCA alone...
  88. ncbi Tissue typing for HFE mutations
    Stuart Raaka
    Hepatology 35:977-8. 2002
  89. ncbi Prevalence of autoimmune liver disease in Alaska Natives
    Kathy J Hurlburt
    Viral Hepatitis Program, Alaska Native Medical Center, Anchorage 99508, USA
    Am J Gastroenterol 97:2402-7. 2002
    ..7). The prevalence of PBC was 16/100,000 (95% CI = 12.9-25.4). CONCLUSIONS: This population-based study demonstrates that the prevalence rates of AIH and PBC in Alaska natives are comparable with reported rates in other populations...
  90. ncbi Synopsis for the Yale Workshop on Hepatocellular Carcinoma
    James M Anderson
    Liver Study Unit, Yale School of Medicine, New Haven, Connecticut 27599-7545, USA
    J Clin Gastroenterol 35:S152-3. 2002
  91. ncbi The impact of chronic hepatitis B on quality of life: a multinational study of utilities from infected and uninfected persons
    Adrian R Levy
    Oxford Outcomes Ltd, Vancouver, BC, Canada
    Value Health 11:527-38. 2008
    ..The objective was to elicit utilities for six health states that occur after infection with the hepatitis B virus from infected and uninfected respondents living in jurisdictions with low and with high CHB endemicity...
  92. ncbi Relationship of steatosis grade and zonal location to histological features of steatohepatitis in adult patients with non-alcoholic fatty liver disease
    Naga Chalasani
    Indiana University School of Medicine, 1050 Wishard Boulevard, Indianapolis, IN 46202, USA
    J Hepatol 48:829-34. 2008
    ..The relationship between severity and zonal location of steatosis and the presence of steatohepatitis and various histological features that define NASH has not been formally studied...